Retatrutide 40mg Pen

Retatrutide (LY-3437943) is an investigational triple receptor agonist peptide that activates three metabolic receptors at once: GLP-1 (glucagon-like peptide 1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. The combined action of all three pathways is the basis for the compound being studied as one of the most potent investigational research compounds in this class.

In the 2023 Phase 2 trial published in *The New England Journal of Medicine*, the 12-mg retatrutide group had a least-squares mean body-weight change of −24.2% at 48 weeks, compared with −2.1% with placebo. In the completed Phase 3 TRIUMPH-1 trial, Lilly’s May 2026 topline results showed average weight changes at 80 weeks of −19.0% with 4mg, −25.9% with 9mg, and −28.3% with 12mg, compared with −2.2% with placebo. In a prespecified 104-week extension among participants with baseline BMI ≥35, the 12-mg group reached an average −30.3% weight change. These Phase 3 figures are sponsor-reported topline results pending full peer-reviewed publication. Retatrutide remains investigational.

Retatrutide is the only compound that attacks the energy balance equation from both sides: reducing appetite through GLP-1 and GIP activity, while simultaneously increasing energy expenditure and fat oxidation through glucagon receptor activation.

Pre-filled FlexiPen format.

No reconstitution, no bacteriostatic water, no syringes. Click-dose accuracy with every administration. The pen ships pre-filled and ready to use: uncap, dial, click.

≥99% purity, Janoshik verified.

Published Retatrutide reports include multiple independent testing methods, including identity, purity, endotoxin, heavy metals, and net peptide content where applicable. View the published reports.

Two-layer independent verification.

ProPeptide publishes two Janoshik reports for the retatrutide pen lineup: the bulk solution that fills the cartridges (batch RET-20-V-2604-001, 99.741% HPLC purity) and a separate finished-cartridge test (batch RET-20-C-2604-001, 99.841% HPLC purity, the 20mg pen). Most pen vendors test only the bulk peptide. We publish both, so you can verify what is actually in your pen.

Research-grade packaging.

Every order ships with the pen device, sterile pen needles (31G, 5mm), product information insert with click-dose reference, and outer carton. Cold-chain insulated packaging maintains the +2 to +8°C range from our facility to your door.

Same-day Dubai delivery.

Orders placed before 4 PM ship same day within Dubai. Outside Dubai, order before 12 PM (noon) for next-day delivery. Orders placed on Saturday will be delivered on Monday, and Sunday delivery is not available outside Dubai. Delivery costs AED 50 below AED 1,000 and is free from AED 1,000. Cold-chain maintained from our facility to your door.

Made and packed in our facility.

Sourced and packed in our own facility. Published batch reports carry a unique reference that maps directly to the documentation shown on the batch reports page.

Retatrutide activates three receptor pathways simultaneously. No other metabolic compound described in the published literature does this.

GLP-1 (glucagon-like peptide 1) receptor

Promotes satiety signaling, slows gastric emptying, and stimulates glucose-dependent insulin secretion. The same pathway targeted by semaglutide and by the GLP-1 component of tirzepatide.

GIP (glucose-dependent insulinotropic polypeptide) receptor

Enhances post-prandial insulin response, has direct effects on adipose tissue, and acts synergistically with GLP-1 to amplify metabolic signaling. The second pathway targeted by tirzepatide. Retatrutide adds a third.

Glucagon receptor

Increases resting energy expenditure, promotes hepatic lipid oxidation, and mobilises stored fat for fuel. The component that distinguishes retatrutide from every other research compound in its class. Semaglutide and tirzepatide do not activate the glucagon receptor.